Genomma Lab Internacional, S.A.B. de C.V.
Genomma Lab Internacional, S.A.B. de C.V. Fundamental Analysis
Genomma Lab Internacional, S.A.B. de C.V. (GNMLF) shows weak financial fundamentals with a PE ratio of 2.11, profit margin of 9.68%, and ROE of 8.49%. The company generates $5.2B in annual revenue with weak year-over-year growth of -5.73%.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 30.9/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.
Fundamental Health Score
We analyze GNMLF's fundamental strength across five key dimensions:
Efficiency Score
ExcellentGNMLF demonstrates superior asset utilization.
Valuation Score
ExcellentGNMLF trades at attractive valuation levels.
Growth Score
WeakGNMLF faces weak or negative growth trends.
Financial Health Score
ExcellentGNMLF maintains a strong and stable balance sheet.
Profitability Score
WeakGNMLF struggles to sustain strong margins.
Key Financial Metrics
Is GNMLF Expensive or Cheap?
P/E Ratio
GNMLF trades at 2.11 times earnings. This suggests potential undervaluation.
PEG Ratio
When adjusting for growth, GNMLF's PEG of -0.02 indicates potential undervaluation.
Price to Book
The market values Genomma Lab Internacional, S.A.B. de C.V. at 1.61 times its book value. This may indicate undervaluation.
EV/EBITDA
Enterprise value stands at 0.39 times EBITDA. This is generally considered low.
How Well Does GNMLF Make Money?
Net Profit Margin
For every $100 in sales, Genomma Lab Internacional, S.A.B. de C.V. keeps $9.68 as profit after all expenses.
Operating Margin
Core operations generate 20.54 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $8.49 in profit for every $100 of shareholder equity.
ROA
Genomma Lab Internacional, S.A.B. de C.V. generates $36.16 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Genomma Lab Internacional, S.A.B. de C.V. generates limited operating cash flow of $344.36M, signaling weaker underlying cash strength.
Free Cash Flow
Genomma Lab Internacional, S.A.B. de C.V. generates strong free cash flow of $599.14M, providing ample flexibility for dividends, buybacks, or growth.
FCF Per Share
Each share generates $0.61 in free cash annually.
FCF Yield
GNMLF converts 56.59% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
2.11
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
-0.02
vs 25 benchmark
P/B Ratio
Price to book value ratio
1.61
vs 25 benchmark
P/S Ratio
Price to sales ratio
0.20
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.70
vs 25 benchmark
Current Ratio
Current assets to current liabilities
1.39
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.08
vs 25 benchmark
ROA
Return on assets percentage
0.36
vs 25 benchmark
ROCE
Return on capital employed
1.27
vs 25 benchmark
How GNMLF Stacks Against Its Sector Peers
| Metric | GNMLF Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 2.11 | 29.88 | Better (Cheaper) |
| ROE | 8.49% | 682.00% | Weak |
| Net Margin | 9.68% | -46037.00% (disorted) | Weak |
| Debt/Equity | 0.70 | 0.42 | Weak (High Leverage) |
| Current Ratio | 1.39 | 4.49 | Neutral |
| ROA | 36.16% | -16420.00% (disorted) | Strong |
GNMLF outperforms its industry in 2 out of 6 key metrics, particularly excelling in ROA, but lagging in ROE.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Genomma Lab Internacional, S.A.B. de C.V.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
31.40%
Industry Style: Defensive, Growth, Innovation
High GrowthEPS CAGR
19.00%
Industry Style: Defensive, Growth, Innovation
High GrowthFCF CAGR
24.51%
Industry Style: Defensive, Growth, Innovation
High Growth